Search Results for “cancer” – Page 64 – media

Another new analgesic has been submitted for marketing application

Vertex (Futai Pharmaceuticals) has a long-standing reputation. It has worked in the field of rare diseases for more than ten years and has created an orphan drug blockbuster trikafta with annual sales of over $10 billion. Today, the company has opened up new horizons in another field. Recently, Vertex announced that the FDA has accepted the marketing application of the Nav1.8 inhibitor VX-548 (Suzetrigine) and granted priority review qualification for the treatment of moderate to severe acute pain. This is a major breakthrough in the field of analgesics and may subvert the competitive landscape of analgesics commercialization. Analgesics have always been valued by the medical community, both in academia and industry. And every pharmacology textbook and medicinal chemistry textbook used as a teaching material cannot avoid a classic drug: morphine. Whether it is its rigid structure of five fused rings or its analgesic and antitussive pharmacological effects, it is well ...
- Source: drugdu
- 62
- October 11, 2024
Over $440 million! Jiahe Biologics’ new dual-antibody drug goes overseas

On August 5, Hong Kong-listed innovative pharmaceutical company Jiahe Biologics (06998.HK) announced that the group entered into a licensing agreement and equity agreement with TRC2004, Inc. on August 2. Pursuant to the License Agreement, the Group has agreed, among other things, to grant TRC2004 an exclusive global license (excluding Mainland China, Hong Kong, Macau and Taiwan) to develop, use, manufacture, commercialize and otherwise exploit GB261. According to the terms of the license agreement and equity agreement, as consideration for the license, the Group will receive a considerable amount of equity in TRC2004, an down payment of tens of millions of US dollars, milestone payments of up to US$443 million, and a single-digit to double-digit share of net sales. percentage tiered royalties. CD3/CD20 inhibitor potential stocks. GB261 is a new type of differentiated CD20/CD3 bispecific T cell engager (TCE) and the first T cell engager (T-cell Engager) that binds to CD3 ...
- Source: drugdu
- 58
- October 11, 2024
ARCH completes $3 billion fundraising! Focus on AI pharmaceuticals

ARCH Venture Partners, an American biotech investment institution, announced the completion of over $3 billion in ARCH Venture Fund XIII fundraising, aimed at supporting the establishment and development of early-stage biotech companies. The 13th fund was established following the 12th fund of $2.975 billion announced in June 2022. “After 38 years, ARCH’s investment philosophy remains the same: we bet on great science and great teams to build breakthrough companies,” said Robert Nelsen, co-founder and managing director of ARCH. “We believe that artificial intelligence and new data-driven insights into biology will help build a more preventive, curative and equitable healthcare system.” “ARCH has a long history of identifying the top forward-looking trends in life science R&D and individuals who drive truly groundbreaking scientific hypotheses,” said Keith Crandell, co-founder and managing director of ARCH. “We are very excited about the pace of innovation and efforts to understand diseases at a deeper level.” ...
- Source: drugdu
- 54
- October 11, 2024
Nearly 2 billion US dollars! What sparks can be ignited between Shiyao Group and AstraZeneca?

On October 7, 2024, Shiyao Group and AstraZeneca reached a heavyweight cooperation agreement, which caused quite a stir in the pharmaceutical industry. So, let’s explore together in what aspects the cooperation between Shiyao Group and AstraZeneca can spark. Lung cancer product Axitinib In the field of lung cancer treatment, Shiyao Group has achieved outstanding results in the treatment of non-small cell lung cancer with EGFR exon 20 insertion mutations (EGFR ex20ins) by combining humanized EGFR monoclonal antibodies with AstraZeneca’s heavyweight product, Axitinib. The relevant research data was published in Nature Communication and has been widely recognized by the international academic community. At present, the key phase II single arm study for this indication is also being carried out smoothly, and good clinical research data has been obtained. It will be applied for market as soon as possible. Based on this good cooperation result, representatives from both parties signed a cooperation ...
- Source: drugdu
- 65
- October 10, 2024
Nearly 2 billion US dollars! What sparks can be ignited between CSPC and AstraZeneca?

Lung cancer product Axitinib In the field of lung cancer treatment, CSPC has achieved outstanding results in the treatment of non-small cell lung cancer with EGFR exon 20 insertion mutations (EGFR ex20ins) by combining humanized EGFR monoclonal antibodies with AstraZeneca’s heavyweight product, Axitinib. The relevant research data was published in Nature Communication and has been widely recognized by the international academic community. At present, the key phase II single arm study for this indication is also being carried out smoothly, and good clinical research data has been obtained. It will be applied for market as soon as possible. Based on this good cooperation result, representatives from both parties signed a cooperation agreement in order to continue the collaboration in the Phase III confirmatory study of this indication. Chen Kangwei, General Manager of AstraZeneca China Oncology Division, stated that the strategic cooperation between the two parties is through a strong alliance ...
- Source: drugdu
- 74
- October 10, 2024
Domestic substitution has entered the sprint period, where is the key?

As one of the hottest terms in 2024, “new quality productivity” is not only an upgrade of economic terms, but also a reflection of the process of era change, hiding the pulse of future industrial development. In many reports and documents issued by the state this year, the field of life sciences is closely linked to new quality productivity. At present, Beijing, Shanghai, Guangdong, Chongqing, Zhejiang, Jiangsu and other provinces and cities have successively issued documents to promote the development of new quality productivity and detailed implementation. At present, the field of life sciences is in a period of rapid change, showing unprecedented vitality. After returning to China after studying abroad, many outstanding scholars have greatly promoted the development of this field, especially the development of basic medical research, biotechnology innovation, biopharmaceuticals, clinical diagnosis and treatment. The development is particularly prosperous. Although the medical industry is treacherous, the rules are ...
- Source: drugdu
- 56
- October 10, 2024
Let’s go to Europe to seek gold

It is a general trend for pharmaceutical companies to go overseas, and the proposition of the times behind it is also advancing with the times. Under the new changes, how to re-examine the gold-mining places such as the United States, Europe, and Southeast Asia? Different countries and regions have different market sizes and policies and regulations. How to examine the pros and cons of the market and formulate a more suitable strategy for going overseas? Everything needs to be answered by the industry. At present, more and more signs show that pharmaceutical companies are no longer just focusing on the “fat meat” of the US market as in the past, and countries and regions such as Europe are becoming more and more important. After being hit repeatedly by the FDA, more and more PD-1s have moved to Europe and been approved for listing. Since the beginning of this year, domestic ...
- Source: drugdu
- 64
- October 10, 2024
Merger of two well-known pharmaceutical companies

On October 7, Jiahe Bio announced that it would acquire Yitong Pharmaceuticals by merger. The name of the merged company will be changed to Yitong Jiahe Pharmaceutical Group Co., Ltd. (hereinafter referred to as “Yitong Jiahe”). The transaction is carried out in the form of a share swap. The price of the proposed merger will be fully settled by issuing consideration shares. After the merger is completed, the shareholders of both parties will jointly hold the equity of Yitong Jiahe, and Jiahe Bio will not have any cash expenditure. According to the listing rules, the transaction constitutes a reverse acquisition of Jiahe Bio. In the merged Yitong Jiahe, the original Yitong Pharmaceutical shareholders accounted for 77.43%, and the original Jiahe Bio shareholders accounted for 22.57%. The actual controller of Yitong Pharmaceutical will become the controlling shareholder of Yitong Jiahe. Based on the rules of Chapter 18A of the Hong Kong ...
- Source: drugdu
- 61
- October 10, 2024
The 2024 “Most Promising New Talent in Biopharmaceuticals” list has been released!

Recently, well-known industry media Endpoint News released the “Biopharma’s Most Exciting Startups in 2024” list, which includes 11 biotechnology companies. These emerging research fields include gene editing, immunotherapy, antibody conjugated drugs (ADCs), weight loss therapy, and multiple other directions. This article will introduce these 11 rising stars (listed in no particular order) to readers, based on this ranking and official information from various companies. Lifordi Immunotherapies is a biotechnology company dedicated to developing ADC therapies for the treatment of autoimmune and inflammatory diseases. Lifordi was founded in 2023 and has secured $70 million in Series A funding from ARCH Venture Partners, 5AM Ventures, and Atlas Venture, with the goal of advancing the main candidate drug LFD-200 into clinical trials and obtaining preliminary data by the end of 2025. Lifordi’s main ADC therapy LFD-200 targets myeloid cells and lymphocytes by targeting highly internalized cell surface facial mask proteins. This therapy has ...
- Source: drugdu
- 80
- October 9, 2024
With a dividend rate of 100% and a profit growth rate of nearly 40%, Dong-E-E-Jiao has resumed high growth

In recent days, various stimulus policies designed from the top have been launched, giving the long-dull stock market a long-lost vitality. On September 30, the Shanghai Composite Index closed up 8.06%, standing above 3,300 points, with a cumulative increase of more than 17% in September; the Shenzhen Component Index closed up 10.67%, with a cumulative increase of more than 26% in September; the ChiNext Index closed up 15.36%, with a cumulative increase of more than 37% in September; all set a record for the largest single-day increase in history. On that day, the turnover of the two markets was 2.593 trillion yuan, setting a record high since 2006. The activity of funds has risen unprecedentedly, and once exceeded the carrying capacity of the exchange server during the session. Players in the market are gearing up to “do a big job”. However, the pharmaceutical industry has been subject to many restrictions ...
- Source: drugdu
- 63
- October 9, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.